PAH News

February 15, 2021February 15, 2021

Altered Fat Metabolism May Contribute to PAH Development

News, PAH News, PH News

Adipose (fat) tissue may contribute to the development of pulmonary arterial hypertension (PAH) due to certain metabolic alterations found, for the first time, in patients and also in rodent models ... Read more

February 12, 2021February 12, 2021

Uptravi Added to Lower Cost Treatment List for PAH Patients in Australia

News, PAH News

Australia’s government has taken a step to ensure that Uptravi (selexipag), an oral therapy for pulmonary arterial hypertension (PAH), is available to people affected by the disease. Janssen’s treatment is now included ... Read more

February 5, 2021February 5, 2021

Umbilical Stem Cell Therapy Alleviates PAH Symptoms in Rats

News, PAH News

Mesenchymal stem cells (MSCs) derived from umbilical cord blood (UBC) showed more therapeutic benefits than those derived from adipose (fatty) tissue or bone marrow in a rat model of pulmonary ... Read more

February 3, 2021February 3, 2021

Pemziviptadil Shows Promise in Small Clinical Trial

News, PAH News

PhaseBio Pharmaceuticals‘s investigational therapy pemziviptadil (PB1046) showed a good safety profile and clinically meaningful effects on physical function in a small clinical trial of three people with pulmonary arterial hypertension ... Read more

February 1, 2021February 1, 2021

Dry-powder Tyvaso Found More Convenient Than Nebulizer for PAH Patients

News, PAH News, PH News

Switching from the approved Tyvaso (inhaled treprostinil) nebulizer to Tyvaso DPI — an investigational dry-powder formulation — is safe, effective, and likely more convenient for people with pulmonary arterial hypertension ... Read more

January 27, 2021January 27, 2021

Incidence of PAH Is 5.8 New Cases Per Million People, Review Finds

CTEPH News, News, PAH News

A total of approximately 5.8 new cases per one million inhabitants was found to be the most accurate value for the worldwide incidence of pulmonary arterial hypertension (PAH), according to ... Read more

January 20, 2021January 20, 2021

Tenax Buys PH Precision Med, Plans Trial for Oral Imatinib

News, PAH News

Tenax Therapeutics has acquired PH Precision Med (PHPM), a private biotech focused on developing imatinib as a treatment for pulmonary arterial hypertension (PAH). “The acquisition of PHPM immediately expands Tenax’s ... Read more

January 8, 2021January 8, 2021

High Creatinine, NT-proBNP Levels Found to Be Mortality Risk Factors

News, PAH News

Elevated blood levels of the kidney disease biomarker creatinine and the heart failure biomarker NT-proBNP were found to be independent predictors of mortality for older people with pulmonary arterial hypertension ... Read more

January 4, 2021January 4, 2021

Atrial Flow Regulator Receives FDA’s Breakthrough Device Designation

News, PAH News

Occlutech’s atrial flow regulator (AFR) — a cardiac implant — received breakthrough device designation from the U.S. Food and Drug Administration for the treatment of pulmonary arterial hypertension (PAH). Breakthrough ... Read more